[PDF] Top 20 La persona con demencia y el Museo Nacional del Prado: el arte de recordar
Has 10000 "La persona con demencia y el Museo Nacional del Prado: el arte de recordar" found on our website. Below are the top 20 most common "La persona con demencia y el Museo Nacional del Prado: el arte de recordar".
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
... for patients with LPS was 237 days (approximately 34 ...of patients with LPS had WD tumors for which the median PFS was not reached, it is difficult to determine whether this prolonged disease ... See full document
323
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
... of MK-8242 in combination with conventional chemotherapeutic agents or following alterations in monotherapy schedule including lower doses/longer term or higher doses/shorter term are important future ... See full document
77
<p>Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development</p>
... a phase I dose- escalation trial examining the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single-agent pexidar- tinib in patients with solid tumors ...41 ... See full document
11
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
... in phase I trials of Aur- ora kinase inhibitors were primarily hematological events, particularly neutropenia [15–18], and DLTs for CSF-1R inhibitor included INR increase, lymphopenia, AST increase, ... See full document
32
Phase II trial of AKT inhibitor MK 2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
... Tumor biopsies (core biopsies and fine needle aspirates) were obtained pretreatment and on day 16 (1 day after third weekly treatment). IHC was performed on core bi- opsies. PTEN IHC was performed in the MD Anderson CLIA ... See full document
10
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
... arm 2: the mean end-of-infusion concentration value was ...DDIs. MK-2206 is not a significant inhibitor or inducer of major CYP enzymes (IC50 >35 μM for CYP3A4, 2C9, and 2D6 inhibition, and has ... See full document
11
First-in-human phase I clinical trial of RG7356, an anti- CD44 humanized antibody, in patients with advanced, CD44- expressing solid tumors
... 9 patients with tumors expressing predominantly CD44s showed some tumor shrinkage (1% to 22% decrease), whereas none was observed in tumors predominantly expressing ... See full document
82
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK 2206) and trastuzumab in patients with HER2 positive solid tumors
... allosteric inhibitor of AKT that requires the PH domain of AKT for activity, but does not interact with the ATP binding ...result, MK-2206 is highly selective for AKT inhibition, has higher potency against ... See full document
16
Amatuximab and novel agents targeting mesothelin for solid tumors
... patients experienced AEs that were considered to be associ- ated with the amatuximab treatment. Among a total of 41 patients in two studies (24 + 17, respectively), 10%–29.4% experienced AEs (including ... See full document
8
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
... PARP-1 inhibitor, attenuates PARP-1 activation. Phase I study of BSI-201 in advanced solid tumors has demonstrated good tolerabil- ity without an identified MTD with dose levels ... See full document
7
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
... many patients with advanced solid ...a phase I dose-escalation trial (part of an overall larger study assessing different drug combina- tions) to explore the efficacy and safety ... See full document
7
Phase I study of pemetrexed with sorafenib in advanced solid tumors
... multiple solid and hematologic malignancies has been strongly associated with a reduced response to chemotherapy and to more rapid disease progression and death ...successor phase II clinical study in ... See full document
51
Dabrafenib and its potential for the treatment of metastatic melanoma
... DTIC patients were still receiving treatment, 44% having crossed over to dabrafenib after disease ...dabrafenib patients (3% complete, 47% partial), and 6% of DTIC patients (2% complete, 4% ... See full document
12
Original Article Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization
... (Table 2; Figure ...in patients with hereditary-non-polyp- osis colon cancer syndromes (HNPCC) or spo- radic colorectal cancers exhibiting microsatel- lite instability (MSI), which are more often local- ... See full document
65
A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors
... (UANL) were developed for the first time in the People’s Republic of China. The intravenous (IV) administration of UANL is considered to improve bioavailability because the nanoparticles bypass the stomach. To date, a ... See full document
6
Targeted agents for the treatment of metastatic melanoma
... in patients with advanced melanoma when compared with stan- dard ...negative Phase III treatment trials, melanoma is now a tumor type for the clinical evaluation of paradigm-shifting therapeutic ... See full document
10
Next generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
... (NCT00777699) I September 2008 80 For gliomas + temozolomide (NCT00704080) I/II May 2010 124 For breast cancer + letrozole (NCT01082068) GDC-0980, Genentech I April 2009 63 Single agent (oral dose ... See full document
67
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
... PD analysis. Tumour biopsy samples were used to undertake transcriptional profiling to assess Notch pathway activity, and immunohistochemical (IHC) analysis of certain Notch target genes. The timing of tissue collection ... See full document
5
Emerging role of multikinase inhibitors for refractory thyroid cancer
... of patients with advanced iodine-refractory thyroid ...in patients with differentiated and medullary thyroid cancer and most of them are showing promising clinical ... See full document
77
A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
... eligible patients were given the following treatment regimen: a single oral dose of 40 mg of ridaforolimus on Day 1; and then, the treatment started from Day 8 with an oral dose of 40 mg of ridaforolimus for five ... See full document
9
Related subjects